|
|
ALF |
|
Vaxjo ID |
346 |
|
Vaccine Adjuvant Name |
ALF |
|
Adjuvant VO ID |
VO_0005525
|
|
Stage of Development |
Clinical Trial |
|
Host Species for Testing |
Mouse |
|
Components |
Army Liposome Formulation (ALF) to an aluminum salt that already has an antigen adsorbed to it might result in improved immune potency of the aluminum-adsorbed antigen |
|
Structure |
Anionic liposome-based adjuvants containing synthetic phospholipids with dimyristoyl fatty acyl groups, cholesterol, and monophosphoryl lipid A (MPLA). |
|
Appearance |
Their physical structures can change based on preparation methods. |
|
Preparation |
ALF is prepared by different methods, and ALFA is formed by adding ALF to AH gel. ALFQA is formed by mixing ALFQ with AH. Antigens are first adsorbed to AH, then ALF or ALFQ are co-adsorbed to form ALFA or ALFQA. |
|
Function |
ALF is composed of a family of anionic liposome-based adjuvants, in which the liposomes contain synthetic phospholipids having dimyristoyl fatty acyl groups, cholesterol and monophosphoryl lipid A (MPLA). For certain candidate vaccines, ALF has been added to aluminum hydroxide (AH) gel as a second adjuvant to form ALFA. |
| References |
Beck et al., 2018: Beck Z, Torres OB, Matyas GR, Lanar DE, Alving CR. Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex. Journal of controlled release : official journal of the Controlled Release Society. 2018; 275; 12-19. [PubMed: 29432824].
|
|
